Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Christopher, Banfield"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 4, Pp 551-562 (2024)
Abstract The objective of this population pharmacokinetic (PK) analysis was to characterize the concentration–time profile of brepocitinib plasma concentration after single‐ and multiple‐oral administration in healthy volunteers (HVs) and patie
Externí odkaz:
https://doaj.org/article/efc00493230549498f4e04dcef08d177
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 10, Pp 553-560 (2020)
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose range 10–200 mg). A kinetic‐pharmacodynamic (K‐PD) model cons
Externí odkaz:
https://doaj.org/article/e532c0ebf64e49048da5a137d5e07b5d
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 7, Pp 478-488 (2019)
Maintaining platelet homeostasis is important to avoid spontaneous bleeding and organ damage. Thrombopoietin, the primary regulator of platelet production, is affected by and acts in part via Janus kinase (JAK)‐signal transducer and activator of tr
Externí odkaz:
https://doaj.org/article/11c901bb45c8440b9890af040dcf0c06
Autor:
Ruolun Qiu, Raman Sharma, Hua Wei, Leonid Kirkovsky, Yifan Zhou, David D. A. Martin, Christopher Banfield, Martin E. Dowty
Publikováno v:
British Journal of Clinical Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8686f5617760c9d0814b819a655d4e4
https://doi.org/10.1111/bcp.15786
https://doi.org/10.1111/bcp.15786
Autor:
Jonathan N. Bauman, Angela C. Doran, Amanda King-Ahmad, Raman Sharma, Gregory S. Walker, Jian Lin, Tsung H. Lin, Jean-Baptiste Telliez, Sakambari Tripathy, Theunis C. Goosen, Christopher Banfield, Bimal K. Malhotra, Martin E. Dowty
Publikováno v:
Drug Metabolism and Disposition. 50:1106-1118
Abrocitinib is an oral once-daily Janus kinase 1 selective inhibitor being developed for the treatment of moderate-to-severe atopic dermatitis. This study examined the disposition of abrocitinib in male participants following oral and intravenous adm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::926208d526384181f37cc80f92c02aa6
https://doi.org/10.1124/dmd.122.000829
https://doi.org/10.1124/dmd.122.000829
Autor:
Lori Ann Cox, Ana B. Pavel, Weidong Zhang, Ester Del Duca, Martin E. Dowty, Yeriel Estrada, Elena Peeva, Karen Page, Anindita Banerjee, Brett A. King, Linda Zhu, Christopher Banfield, Michael S. Vincent, Aisleen Diaz, Emma Guttman-Yassky, Ning Zhang
Publikováno v:
Journal of Allergy and Clinical Immunology. 149:1318-1328
Background Janus kinase (JAK) inhibitors have shown encouraging results in the treatment of alopecia areata (AA), an autoimmune form of hair loss, in small, uncontrolled studies and case reports. Objective To conduct a biopsy sub-study during the ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91eb2c78d9ca0785c7895b699ec611b5
https://doi.org/10.1016/j.jaci.2021.10.036
https://doi.org/10.1016/j.jaci.2021.10.036
Autor:
Megan N Landis, Stacy R Smith, Gabriel Berstein, Gerald Fetterly, Pranab Ghosh, Gang Feng, Vivek Pradhan, Sudeepta Aggarwal, Christopher Banfield, Elena Peeva, Michael S Vincent, Jean S Beebe, Sanela Tarabar
Publikováno v:
British Journal of Dermatology.
Background Plaque psoriasis (PsO) is an inflammatory skin disease driven, in part, by the activation of Janus kinase (JAK) signalling pathways. Objectives To assess the efficacy and safety of multiple doses of topical brepocitinib, a tyrosine kinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c050877b4031a6cf8082f8c53d27a09
https://doi.org/10.1093/bjd/ljad098
https://doi.org/10.1093/bjd/ljad098
Autor:
William J. Sandborn, Silvio Danese, Jaroslaw Leszczyszyn, Jacek Romatowski, Engin Altintas, Elena Peeva, Mina Hassan-Zahraee, Michael S. Vincent, Padmalatha S. Reddy, Christopher Banfield, Mikhail Salganik, Anindita Banerjee, Jeremy D. Gale, Kenneth E. Hung
Publikováno v:
Clinical Gastroenterology and Hepatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35192dcc5175fc4d32e0f0502ea87be6
https://doi.org/10.1016/j.cgh.2022.12.029
https://doi.org/10.1016/j.cgh.2022.12.029
Autor:
Karen Page, Emma Guttman-Yassky, Christopher Banfield, Linda H. Chen, Lori Ann Cox, Brett A. King, Weidong Zhang, Brittany G. Craiglow, Rodney Sinclair, Anindita Banerjee, Michael S. Vincent, Ana B. Pavel, Linda Zhu, Elena Peeva
Publikováno v:
Journal of the American Academy of Dermatology. 85:379-387
Background Alopecia areata (AA) is an autoimmune form of hair loss with limited treatments. Objective To evaluate the efficacy and safety of the Janus kinase inhibitors ritlecitinib and brepocitinib in patients who have AA with ≥ 50% scalp hair los
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6da1ad9d7f27223752fc52e4693a2fc7
https://doi.org/10.1016/j.jaad.2021.03.050
https://doi.org/10.1016/j.jaad.2021.03.050
Autor:
Megan N. Landis, Mark Arya, Stacy Smith, Zoe Draelos, Lisa Usdan, Sanela Tarabar, Vivek Pradhan, Sudeepta Aggarwal, Christopher Banfield, Elena Peeva, Michael S. Vincent, Vanja Sikirica, Jason Xenakis, Jean S. Beebe
Publikováno v:
The British journal of dermatologyReferences. 187(6)
Background Atopic dermatitis (AD) is a prevalent inflammatory, pruritic skin disease. The Janus kinase (JAK) pathway is a treatment target. Objectives To assess the efficacy, safety and pharmacokinetics of topical cream brepocitinib, a small-molecule
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cef62276a1c4d898f2ddd859b40f148
https://pubmed.ncbi.nlm.nih.gov/36199210
https://pubmed.ncbi.nlm.nih.gov/36199210